GSK Looks To India, Singapore

UK-based drugmaker GlaxoSmithKline (GSK) has indicated that in future it will be conducting more of its R&D in Asia, with Singapore and India looking like the company's favoured locations. The company expects to have an Indian-originated compound on the market within five years.

To read the full article, please choose one of the following options: